Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

A Phase 2a, Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of LCB01-0371 (Delpazolid) as Add-on Therapy in Patients With Refractory Mycobacterium Abscessus Complex Pulmonary Disease

The purpose of this study is to evaluate the efficacy and safety of delpazolid add-on therapy in Patients with Refractory Mycobacterium abscessus Complex Pulmonary disease

Study Overview

• Status: Active, not recruiting
• Conditions: Mycobacterium Abscessus Infection; Nontuberculous Mycobacterium Infection
• Intervention / Treatment: Drug: Delpazolid

Detailed Description

Delpazolid, which demonstrates effects similar to other oxazolidinone-class drugs and has confirmed good safety, aims to evaluate its efficacy in MABC-PD patients who are unresponsive to guideline-based treatments

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Phase 2

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Asan Medical Center
  • Seoul, Korea, Republic of
    • Samsung Medical Center
  • Seoul, Korea, Republic of
    • Severance Hospital
  • Seoul, Korea, Republic of
    • Seoul National University Bundang Hospital
  • Seoul, Korea, Republic of
    • Bundang Seoul National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Pre-screening: Adults aged 19 years or above
• Pre-screening: Patients diagnosed with MABC (including subspecies abscessus, bolletii, and massiliense) pulmonary disease in radiologic and microbiologic evaluations
• LCB01-0371 MIC ≤ 8 μg/mL for MABC

• Patients who continue to show positivity for MABC even after treatments based on the guidelines of ATS/ERS/ESCMID/IDSA for at least 6 months prior to screening, and who meet all of the following criteria:

  1. Patients who have been confirmed positive at least once in the last sputum or bronchoscopy sample culture performed prior to screening
  2. Patients who have not achieved culture conversion (at least 3 consecutive negative mycobacteria cultures in the sputum or bronchoscopy sample collected at an interval of at least 4 weeks) within 6 months prior to screening
• Patients who can voluntarily expectorate sputum at screening
• Patients with a life expectancy of 12 weeks or more

• Patients with adequate organ function who meet the following criteria:

  1. Hemoglobin > 9.0 g/dL (without transfusion within 2 weeks prior to measurement)
  2. Absolute neutrophil count ≥ 1,500/µL (without administration of G-CSF within 2 weeks prior to measurement)
  3. Platelet ≥ 100,000/µL
  4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
  5. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN
  6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance >30 mL/min (calculated with the Cockcroft-Gault formula)
• Patients who voluntarily provided a written consent to participate in the clinical study

Exclusion Criteria:

• Patients who cannot swallow the study drug tablet due to dysphagia, nasogastric tube insertion, etc.
• Patients diagnosed with cystic fibrosis
• Patients who have received a lung transplant
• Patients with disseminated or extrapulmonary nontuberculous mycobacteria
• Patients with known active pulmonary tuberculosis
• Patients with NTM infections other than MABC
• Patients with an active pulmonary malignancy within 1 year prior to screening or Patients with other malignancies that require chemotherapy or radiotherapy
• Patients who has received linezolid for MABC treatment within 3 months prior to screening
• Patients with known HIV positivity or a suspected infection thereof or Patients with a known active hepatitis B or C infection

• Patients who currently have a clinically significant cardiovascular disease

  1. Patients with severe cardiac failure (New York Heart Association [NYHA] class III/IV) that occurred within 24 weeks prior to screening
  2. Patients with pulmonary embolism or deep venous thrombosis that occurred within 24 weeks prior to screening
• Patients whose multidrug therapy for treatment of MABC was changed within 4 weeks prior to screening (Discontinuation, dose adjustment, change of administration route, etc., are allowed.)

• Patients for whom the administration of contraindicated concomitant drugs that correspond to the following cannot be discontinued during the clinical study or for whom their administration is necessary

  1. Administration of a new antibacterial agent for the prioritized treatment of NTM, especially MABC, other than background therapy
  2. Monoamine oxidase inhibitors
  3. Serotonin reuptake inhibitor or serotonin 5-HT1 receptor agonists
  4. Meperidine or buspirone
  5. Drugs that lower epilepsy threshold; tramadol, etc.
  6. Tricyclic Antidepressant
  7. Other investigational products: If there is a history of administration within 30 days prior to screening, it falls under the exclusion criteria.
• Pregnant or breastfeeding women and women of childbearing potential who do not agree to practice appropriate contraceptive methods*:

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: delpazolid; In addition to background therapy for MABC, patients will be given orally three tablets (400 mg/tablet) of LCB01-0371 for 12 weeks.	Drug: Delpazolid; Three tablets (400 mg/tablet) of delpazolid will be orally administered once daily for 12 weeks. After 3 months (12 weeks) of administration, if the investigator determines that there are clinical benefits, an additional extended treatment of up to 9 months (40 weeks) may be given, amounting to 1 year of treatment in total.; Other Names: LCB01-0371

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
semi-quantitative scale (SQS) change versus baseline	The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load.	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sputum culture conversion rate	neg culture x3( sputum conversion)	12 weeks
Time to culture conversion	from the date of assignment to the first negative result.	12 weeks
Time to positivity in the liquid culture automated system (MGIT)	time to detection of positive in MGIT system	12 weeks
Negative sputum culture rate at each time point after baseline	negative culture results in MGIT and solid media	12 weeks
Change from baseline in the inflammatory marker	erythrocyte sedimentation rate [ESR]) at each time point	12 weeks
Six-minute walk test	Six-minute walk test	12 weeks
Change from baseline in SQS	The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load.	4 weeks and 8 weeks
Quality of Life Questionnaire-Bronchiectasis	The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.	12 weeks
Change from baseline in the CT score	The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations. Descriptive statistics for each point in time are presented, and intra-group comparison of CT score changes at 12 weeks compared to baseline	12 weeks
Extended administration	1) SQS at each time point compared to baseline in subjects receiving extended administration; The SQS using liquid media and solid media will be scored a point of 1-7, with lower scores representing a reducing bacterial load 2) Inflammatory markers at each time point compared to baseline in subjects receiving extended administration; erythrocyte sedimentation rate 3) CT scores at each time point compared to baseline in subjects receiving extended administration; The CT scan score will be transformed onto a scale of 0-42, with lower scores representing improved lung presentations.4) QOL-B change at each time point compared to baseline in subjects receiving extended administration; The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.5) sputum culture negative conversion at each time point compared to baseline in subjects receiving extended administration; negative culture results in MGIT and solid media	After 12 weeks

Collaborators and Investigators

• Sponsor: LigaChem Biosciences, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): January 16, 2024
• Primary Completion (Estimated): November 30, 2025
• Study Completion (Estimated): December 30, 2026

Study Registration Dates

• First Submitted: August 16, 2023
• First Submitted That Met QC Criteria: August 16, 2023
• First Posted (Actual): August 22, 2023

Study Record Updates

• Last Update Posted (Actual): August 22, 2025
• Last Update Submitted That Met QC Criteria: August 18, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: NTM; MABC; MABC-PD; rapid growers
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Actinomycetales Infections; Infections; Communicable Diseases; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Anti-Bacterial Agents; Anti-Infective Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Synthesis Inhibitors; Delpazolid
• Other Study ID Numbers: LCB01-0371-2004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No